Clinical trials: Cytokines
SARS-CoV2 Infection
Efficacy and Safety of EXOSOME-MSC Therapy to Reduce Hyper-inflammation In Moderate COVID-19 Patients
In COVID-19 infection caused by the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is a dysregulation of the immune system response that causes cytokine storm syndrome.
- Trial name
- EXOMSC-COV19 (NCT05216562)
- Testing
- Exosome-MSC Intravenous injection, COVID-19 Standard Treatment
- Where
- 3 sites in Indonesia
- Volunteers
- 60 people
- Sponsor
- Dermama Bioteknologi Laboratorium
COVID-19
Hemoperfusion Efferon СT for the Extremely Severe Form of COVID-19
The development of acute respiratory and renal failure of COVID-19 patients is associated with an excessive immune response and hyperproduction of anti-inflammatory cytokines, which leads to impaired endothelial function and a…
- Trial name
- NCT06402279
- Testing
- Efferon CT therapy
- Where
- Russia
- Volunteers
- 130 people
- Sponsor
- Efferon JSC
Natural Killer Cell Cytokine Production
Measurement of NK Cell Activity in Whole Blood in Subjects Being Screened for Colorectal Cancer Using Colonoscopy
This study will look at measuring the activity of natural killer (NK) cells using the in vitro diagnostic device NK Vue in subjects being screened for colorectal cancer using colonoscopy.
- Trial name
- NCT02291198
- Testing
- NK Vue: NK cell activity in stimulated whole blood
- Where
- Canada
- Volunteers
- 1,081 people, healthy volunteers welcome
- Sponsor
- ATGen Canada Inc
Atherosclerosis
Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM)
This will be an exploratory, open-label, single sequence, two part study (Part A and an optional Part B). The aim of this study will be to assess whether systemic inhibition of Lipoprotein associated phospholipase A2 (Lp-PLA2) in…
- Trial name
- NCT02058641
- Testing
- Darapladib
- Where
- United Kingdom
- Volunteers
- 9 people
- Sponsor
- GlaxoSmithKline
Diffuse Large B-cell Lymphoma (DLBCL)
A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Phase I/II, open-label, multicenter, prospective study.
- Trial name
- NCT02957019
- Testing
- L19-IL2 - Ph I, L19-IL2 at RD - Ph II, Rituximab
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- Philogen S.p.A.
Gambling Addiction
Validation of Kaihani Score for Gambling Addiction
The Kaihani Score is a blood based means of assessing molecules believed to be associated with gambling addiction. The current clinical trial will assess the Kaihani Score in 3 groups: Group 1: 10 patients with no personal or…
- Trial name
- NCT04648007
- Testing
- Kaihani Score
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Therapeutic Solutions International
Coronavirus, COVID
A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19
This was a randomized, double-blind, placebo-controlled, 29-day study to assess the efficacy and safety of axatilimab plus standard of care (SOC), compared with placebo plus SOC, in participants with respiratory signs and…
- Conditions
- Coronavirus, COVID, ARDS, Cytokine Storm
- Trial name
- NCT04415073
- Testing
- SNDX-6352
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Syndax Pharmaceuticals
Chronic Granulomatous Disease (CGD)
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
This research study is designed to assess the prevalence of specific antibodies and inflammatory cytokines in adult and pediatric participants with CGD.
- Trial name
- NCT06605378
- Where
- 52 sites in United States, United Kingdom
- Volunteers
- 60 people
- Sponsor
- Ensoma
Multiple Myeloma
Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients
This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of BHV-1100 plus cytokine induced memory-like…
- Trial name
- NCT04634435
- Testing
- BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Constipation, Anorexia
Effectiveness of Bacillus Spore Probiotics in Reducing Constipation, Anorexia, and Slow Weight Gain in Children
Constipation is rising globally and is a health concern in Asia. Prolonged constipation, without proper care, can lead to complications affecting a child's physical and psychological development, causing significant health and…
- Conditions
- Constipation, Anorexia, Weight Gain
- Trial name
- NCT06154525
- Testing
- RO water, LiveSpo Preg-Mom, LiveSpo KIDS
- Where
- Vietnam
- Volunteers
- 201 people
- Sponsor
- Anabio R&D
Inflammation, Interleukin-1beta
Effect on Cytokines IL-1ß, TNF-α, IL-4, and Total Bacterial Load of a Composition Comprising Olive Oil, Trimethylglycine and Xylitol Delivered as a Toothpaste
The goal of this clinical trial is to learn if a novel composition comprising olive oil, trimethylglycine and xylitol, affects salivary levels of IL-1ß, TNF-α and IL-4 in a group of periodontally healthy, normal and…
- Conditions
- Inflammation, Interleukin-1beta, TNF-α, Cytokine Levels
- Trial name
- NCT06786910
- Testing
- Toothpaste with olive oil, trimethylglycine and xylitol, Toothpaste without olive oil, trimethylglycine nor xylitol
- Where
- Spain
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Mucosa Innovations, S.L.
Rheumatoid Arthritis
Combination Therapy of F8IL10 and Methotrexate in Rheumatoid Arthritis Patients
Phase I, multicenter, open-label, dose escalation study to test the efficacy and safety of F8IL10 and methotrexate when given as a combination in rheumatoid arthritis patients.
- Trial name
- NCT02076659
- Testing
- F8IL10, Methotrexate
- Where
- 5 sites in Italy
- Volunteers
- 36 people
- Sponsor
- Philogen S.p.A.
Healthy
Safety and Immune Enhancing Effects of Acute Dosing of COLD-fX in Healthy Adults
Subjects will be asked to participate in a four day research study of the immune system effects and safety of short-term acute dosing of Cold-fX.
- Trial name
- NCT00435968
- Testing
- CVT E002 (Cold-fX)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- CV Technologies
Advanced Solid Tumours
A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours
This is a Phase I/II study for patients with solid tumors and renal cell carcinoma (RCC; for the Phase II part). L19-IL2 is a tumor targeted immunocytokine constituted of a single chain Fragment variable (scFv) format directed…
- Trial name
- NCT01058538
- Testing
- L19IL2
- Where
- 2 sites in Germany, Italy
- Volunteers
- 33 people
- Sponsor
- Philogen S.p.A.
Depressive Disorder, Major
Clinical Study to Test a New Drug to Treat Major Depression
In this randomized, double-blind, multi-centre, placebo controlled, exploratory, adaptive design study, the antidepressant and plasma cytokine lowering effects of the GW856553 will be investigated in adult subjects diagnosed with…
- Trial name
- PKI113009 (NCT00976560)
- Testing
- GW856553
- Where
- 21 sites in United States, Bulgaria and 3 more
- Volunteers
- 128 people
- Sponsor
- GlaxoSmithKline
Cytokine Release Syndrome, Immune Effector Cell-Associated Neurotoxicity Syndrome
RPM Signals in Outpatient CAR T Therapy
The goal of this observational study is to learn how patients' vital signs and symptoms change during outpatient CAR T-cell therapy with lisocabtagene maraleucel (liso-cel), a type of cancer treatment.
- Conditions
- Cytokine Release Syndrome, Immune Effector Cell-Associated Neurotoxicity Syndrome, B-Cell Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT07882732
- Volunteers
- 125 people
- Sponsor
- Current Health
Solid Tumor, Advanced Solid Tumor
NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer
Parts 1 and 2 The primary purpose of this study is to understand the safety of NL-201 when given intravenously as monotherapy in patients with advanced cancer to evaluate tolerability and to identify a recommended dose and…
- Trial name
- NCT04659629
- Testing
- NL-201, Pembrolizumab Injection [Keytruda]
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 59 people
- Sponsor
- Neurogene Inc.
Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection
Combination Therapy of L19IL2 and Gemcitabine in Advanced Pancreatic Cancer Patients
Systemic treatment for advanced, non-resectable pancreatic cancer still having minimal impact on the survival of patients. Even with the application of more potent gemcitabine-based regimens, survival of more than 1 year is…
- Trial name
- NCT01198522
- Testing
- L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine
- Where
- 5 sites in Germany, Italy
- Volunteers
- 28 people
- Sponsor
- Philogen S.p.A.
Burns
ST266 Versus Standard Care In Treating Partial Thickness Burns
The objective of this protocol is to perform a safety and dose-determination efficacy clinical trial in patients having a degree of partial-thickness burn wounds.
- Trial name
- NCT00886470
- Testing
- ST266
- Where
- 14 sites in United States
- Volunteers
- 16 people
- Sponsor
- Noveome Biotherapeutics, formerly Stemnion
Head and Neck Squamous Cell Carcinoma, Melanoma
RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma
The purpose of this study is to assess the safety and tolerability of escalating doses of RPTR-168 as a monotherapy in patients with HPV-16 E6/E7 positive tumors (HNSCC, cervical) and melanoma.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Melanoma, Cervical Cancer
- Trial name
- NCT04762225
- Testing
- RPTR-168
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Repertoire Immune Medicines